Genprex Inc (GNPX)

[breezy1]

One patient in the Phase II combination trial had a Complete Response, or CR, under the Response Evaluation Criteria in Solid Tumors, or RECIST. This patient, a 58 year old female, upon enrollment in the study had metastatic NSCLC status following 6 cycles of pemetrexed and carboplatin and 2 cycles of maintenance pemetrexed with cancer progression. The patient’s tumor has EGFR exon 18 and 20 missense mutations, which are not sensitive to erlotinib. This patient had disappearance of both the lung primary tumor and the lung, liver, and lymph node metastases.

This is their previously “main” product